Exicure Files S-1 for Continuous Offering, Signals Capital Raise
Ticker: XCUR · Form: S-1 · Filed: Jul 11, 2025 · CIK: 1698530
| Field | Detail |
|---|---|
| Company | Exicure, Inc. (XCUR) |
| Form Type | S-1 |
| Filed Date | Jul 11, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: S-1 Filing, Biotechnology, Pharmaceuticals, Capital Raise, Smaller Reporting Company, Continuous Offering, SEC Filing
Related Tickers: XCUR
TL;DR
**Exicure's S-1 filing is a necessary capital grab for a small biotech, but expect dilution before any potential upside.**
AI Summary
EXICURE, INC. (XCUR) filed an S-1 registration statement on July 11, 2025, indicating a proposed sale of securities on a delayed or continuous basis under Rule 415. The company, a non-accelerated and smaller reporting company, is headquartered in Redwood City, CA, with its business phone number (847) 673-1700. While specific revenue and net income figures are not detailed in the provided excerpt, the filing signals a capital-raising event for the pharmaceutical preparations company. Key business changes include its status as a smaller reporting company, which impacts regulatory compliance. Risks are inherent in the pharmaceutical sector, particularly for smaller companies reliant on successful drug development and market adoption. The strategic outlook involves leveraging this offering to fund ongoing operations and potentially advance its pipeline, though the exact use of proceeds is not specified in this initial filing. The company's agent for service is Andy Yoo, President and CEO.
Why It Matters
This S-1 filing by Exicure (XCUR) signals an upcoming capital raise, crucial for a smaller reporting company in the capital-intensive pharmaceutical industry. For investors, it means potential dilution but also a lifeline for funding R&D and operations, impacting future stock performance. Employees and customers will watch for how this funding translates into product development and stability. In a competitive biotech landscape, securing capital is paramount for survival and innovation, especially for companies like Exicure that are not large accelerated filers.
Risk Assessment
Risk Level: high — The risk level is high because Exicure is a 'smaller reporting company' and a 'non-accelerated filer,' indicating limited financial resources and market capitalization. The pharmaceutical industry itself carries inherent high risks related to drug development, regulatory approvals, and market adoption, none of which are mitigated by this filing, which primarily signals a capital raise.
Analyst Insight
Investors should exercise caution and conduct thorough due diligence on Exicure's pipeline and financial health before considering an investment. The S-1 indicates a capital raise, which often leads to dilution; wait for details on the offering size and use of proceeds.
Financial Highlights
- revenue
- $0
- operating Margin
- N/A
- total Assets
- $0
- total Debt
- $0
- net Income
- $0
- eps
- $0
- gross Margin
- N/A
- cash Position
- $0
- revenue Growth
- N/A
Key Numbers
- 0001698530 — Central Index Key (CIK) (Unique identifier for Exicure, Inc. with the SEC)
- 2025-07-11 — Filing Date (Date S-1 was filed with the SEC)
- 333-288658 — SEC File Number (Registration statement number for the offering)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
Key Players & Entities
- EXICURE, INC. (company) — registrant filing S-1
- Andy Yoo (person) — President and Chief Executive Officer, agent for service
- Margaret I. Butler (person) — Baker & Hostetler LLP, counsel
- Baker & Hostetler LLP (company) — legal counsel for the registrant
- Securities and Exchange Commission (regulator) — regulatory body for S-1 filing
- Max-1 Acquisition Corp (company) — former name of Exicure, Inc.
- Delaware (regulator) — state of incorporation
- 847-673-1700 (dollar_amount) — business phone number
FAQ
What is the purpose of Exicure's S-1 filing?
Exicure's S-1 filing on July 11, 2025, is a registration statement under the Securities Act of 1933 for a proposed sale of securities on a delayed or continuous basis pursuant to Rule 415, indicating a capital-raising event.
Who is the CEO of Exicure, Inc. and agent for service?
Andy Yoo is the President and Chief Executive Officer of Exicure, Inc. and also serves as the agent for service for the company, with an address at 400 Seaport Court, Suite 102, Redwood City, CA 94063.
What is Exicure's regulatory status according to the S-1?
According to the S-1 filing, Exicure, Inc. is designated as a 'non-accelerated filer' and a 'smaller reporting company,' which impacts its reporting requirements and market perception.
Where are Exicure's principal executive offices located?
Exicure's principal executive offices are located at 400 Seaport Court, Suite 102, Redwood City, CA 94063, with a business phone number of (847) 673-1700.
What was Exicure, Inc.'s former company name?
Exicure, Inc.'s former company name was Max-1 Acquisition Corp, with the name change occurring on February 21, 2017.
What type of industry is Exicure, Inc. in?
Exicure, Inc. operates in the 'Pharmaceutical Preparations' industry, as indicated by its Standard Industrial Classification (SIC) code 2834.
When was Exicure's S-1 registration statement filed?
Exicure's S-1 registration statement was filed with the Securities and Exchange Commission on July 11, 2025.
What is the significance of Rule 415 for Exicure's offering?
Rule 415 allows Exicure to offer securities on a delayed or continuous basis, providing flexibility in timing and execution of the capital raise, which is common for companies seeking ongoing funding.
Who is the legal counsel for Exicure's S-1 filing?
Margaret I. Butler of Baker & Hostetler LLP, located at 45 Rockefeller Plaza, New York, NY 10111, is listed as counsel for Exicure's S-1 filing.
What is the fiscal year end for Exicure, Inc.?
The fiscal year end for Exicure, Inc. is December 31, as stated in the company data section of the filing.
Risk Factors
- Reliance on Key Personnel [high — operational]: The company's success is heavily dependent on the continued service of its key executive officers, including Andy Yoo, President and CEO. The loss of any of these individuals could materially and adversely affect the company's ability to execute its business strategy and achieve its objectives.
- Need for Additional Capital [high — financial]: Exicure, Inc. has a history of operating losses and expects to incur further losses. The company's ability to continue as a going concern is dependent on its ability to secure additional financing. This S-1 filing indicates a need to raise capital to fund operations and advance its pipeline.
- Uncertainty of Drug Development and Commercialization [high — market]: As a pharmaceutical preparations company, Exicure's business is subject to the inherent risks of drug development, including clinical trial failures, regulatory hurdles, and market acceptance. There is no assurance that any of its product candidates will receive regulatory approval or achieve commercial success.
- Regulatory Approval Process [high — regulatory]: The development and commercialization of pharmaceutical products are subject to extensive regulation by governmental authorities, such as the FDA. Obtaining regulatory approval is a lengthy, expensive, and uncertain process, and failure to obtain such approval for any of its product candidates would have a material adverse effect on the business.
- Competition in the Pharmaceutical Industry [medium — market]: The pharmaceutical industry is highly competitive. Exicure faces competition from numerous companies, including large pharmaceutical companies and smaller biotechnology firms, many of which have greater financial resources and established market positions.
Industry Context
Exicure, Inc. operates in the highly competitive pharmaceutical preparations industry. This sector is characterized by significant research and development costs, lengthy regulatory approval processes, and intense competition from both large, established pharmaceutical companies and smaller biotechnology firms. Key trends include a focus on novel drug discovery, advancements in biotechnology, and evolving regulatory landscapes.
Regulatory Implications
As a pharmaceutical company, Exicure, Inc. is subject to stringent regulatory oversight by bodies like the FDA. The S-1 filing itself is a regulatory requirement for public offerings. The company's status as a smaller reporting company may allow for some scaled disclosure, but core compliance with pharmaceutical regulations remains critical.
What Investors Should Do
- Review the full S-1 filing for detailed financial statements and use of proceeds.
- Assess the company's drug pipeline and clinical trial progress.
- Evaluate the management team's experience and track record.
- Monitor future SEC filings for updates on financial performance and regulatory milestones.
Key Dates
- 2025-07-11: Filing of S-1 Registration Statement — Indicates the company's intention to raise capital through a public offering of securities.
- 2017-02-21: Date of Name Change from Max-1 Acquisition Corp — Marks a significant corporate restructuring or rebranding event prior to the current S-1 filing.
Glossary
- S-1 Registration Statement
- A form filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer their securities to the public. It contains detailed information about the company's business, financial condition, and management. (This is the primary document filed by Exicure, Inc. to initiate its public offering, providing essential disclosure to potential investors.)
- Rule 415
- A rule that permits securities to be registered for the sale on a delayed or continuous basis. This is often referred to as a 'shelf registration'. (Exicure, Inc. is utilizing Rule 415, indicating flexibility in how and when it will offer its securities to the public.)
- Smaller Reporting Company
- A company that meets certain criteria related to public float and annual revenues, allowing for scaled disclosure requirements. (Exicure, Inc. is classified as a smaller reporting company, which may affect the extent of financial and other information it must provide in its SEC filings.)
- SIC Code 2834
- Standard Industrial Classification code for Pharmaceutical Preparations. (This code categorizes Exicure, Inc.'s primary business activity within the pharmaceutical industry.)
- Agent for Service
- An individual or entity designated to receive legal documents on behalf of a company. (Andy Yoo is designated as the agent for service, indicating his role in handling official communications and legal notices for Exicure, Inc.)
Year-Over-Year Comparison
As this is an initial S-1 filing for a capital raise, there is no direct prior S-1 filing to compare against. However, the company's designation as a 'smaller reporting company' and 'non-accelerated filer' suggests it may have previously operated under different reporting thresholds or as a private entity. The filing indicates a strategic move to access public markets for funding, implying a need for capital that may not have been met through private means.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on July 11, 2025 by Andy Yoo regarding EXICURE, INC. (XCUR).